Notice
Recent Posts
Recent Comments
Link
| 일 | 월 | 화 | 수 | 목 | 금 | 토 |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | 31 |
Tags
- GLP-1 치료제
- GLP-1
- GLP-1치료제
- Novo Nordisk
- vk2809
- tirzepatide
- 제약바이오
- 노보노디스크
- VKTX
- ct-996
- tern-601
- 2024 easl
- Viking Therapeutics
- Mash
- orforglipron
- GPCR
- Pegozafermin
- 비만치료제
- 경구용 glp-1
- VK2735
- glp-1 비만
- 바이오스터디
- CAR-T in autoimmune
- Nash
- gsbr-1290
- Efruxifermin
- structure therapeutics
- CAR-T
- danuglipron
- lilly
Archives
- Today
- Total
제약바이오 츄롸이츄롸이!~
Tags
- 비만치료제
- GLP-1 치료제
- orforglipron
- VK2735
- CAR-T
- gsbr-1290
- Viking Therapeutics
- danuglipron
- VKTX
- tern-601
- 경구용 glp-1
- Novo Nordisk
- GLP-1
- 제약바이오
- Mash
- 바이오스터디
- 노보노디스크
- tirzepatide
- Nash
- lilly
- glp-1 비만
- Pegozafermin
- Efruxifermin
- GLP-1치료제
- CAR-T in autoimmune
- GPCR
- ct-996
- 2024 easl
- structure therapeutics
- vk2809
- MASH 치료제
- NASH 치료제
- 나스닥바이오
- ETNB
- MDGL
- AKRO
- 미국주식
- 세포치료제
- 릴리
- 2024 easd
- allogeneic cell therapy
- denifanstat
- survodutide
- lotiglipron
- 자가면역질환 치료제
- 2024 AACR
- Semaglutide
- Resmetirom
- 경구용 비만치료제
- 동종세포치료제
- 자가면역질환치료제
- NASH치료제
- CAR-NK
- SNAC
- BDTX
- anti-cd19
- inebilizumab
- amycretin
- sana biotechnology
- 2024 eular
- 동종 세포치료제
- glp-1 경구
- nash/mash
- T-cell engager
- 2024 ASCO
- tovorafenib
- RAF 저해제
- RAF inhibitor
- CULLINAN ONCOLOGY
- RAPT therapeutics
- GLP-1/GIP
- RYBELSUS
- Oncology Innovation Day
- MASH치료제
- C797S
- EGFR inhibitor
- CAR-T 치료제
- Allogeneic CAR-T
- CRBU
- Black Diamond Therapeutics
- 스터디노트
- Ozempic
- 오젬픽
- FGF21
- 이중항체
- RAPT
- EGFR
- Tern
- 화이자
- Pfizer
- 항암제
- cagrisema
- maritide
- obesity week
- retatrutide
- 89bio
- akero therapeutics
- 2024 ash
- 2024 acr
- tafasitamab
- blinatumomab
- gmg
- anti-ox40
- rocatinlimab
- braf inhibitor
- braf v600x
- bidac degrader
- cft1946
- c4 therapeutics (nasdaq: cccc)
- amycretin oral
- lilly 릴리
- novo nordisk 노보노 디스크
- roche 로슈
- glp-1 비만치료제
- 2024 wclc
- 1l nsclc
- ak112
- pd-1xvegfr
- akeso bio
- summit therapeutics
- ivonescimab
- fc effector function
- rilvegostomig
- vibostolimab
- tiragolumab
- domvanalimab
- dostarlimab
- belrestotug
- glp-1 경구용
- rgt-075
- cd47
- mhc ii knock-out
- mhc i knock-out
- hypoimmune
- terns pharma
- nasdaq: tern
- cd3 engager
- blincyto
- blintatumomab
- 자가세포치료제 vs. 동종세포치료제
- allogeneic car-t in 자가면역
- 2024 ada
- calcitonin
- amylin
- glp-1 비만 치료제
- lortiglipron
- oral glp-1
- ft522
- f819
- 자가면역질환 세포치료제
- CLN-978
- CGEM
- Cullinan Therapeutics
- EGFR 저해제
- FDA 허가
- Day One Biopharma
- allogeneic CAR
- mRNA-4571
- BlakcDiamond Therapeutics
- Deciphera
- Kinnate
- Erasca
- DayOne Biopharma
- exarafenib
- belvarafenib
- naporafenib
- ARRIVENT
- Amivantamab
- EGFR Exon20ins
- ORIC Pharmaceuticals
- NKARTA
- 자가면역질환 CAR-T
- CPI 치료제
- KEYTRUDA
- Carmot Therapeutics
- GLP-1/GIP Dual Agonist
- REZDIFFRA
- Oral Formuatlion
- Oral Formulation
- Product Supply
- Research & Early Development
- Capital Market Day
- Capital Market Day 2024
- ADC 치료제
- 이중항체 치료제
- 2023 ESMO
- FGF21 Agonist
- SNDX
- Menin 저해제
- Menin Inhibitor
- THb agonist
- FGFR21
- GCG
- GIP
- EGFR저해제
- 자가면역치료제
- CAR세포치료제
- Allogeneic
- Altimmune
- ESMO
- Novartis
- Caribou Biosciences
- BMEA
- 위고비
- 보로노이
- NKTX
- ORIC
- autoimmune
- CAR-T치료제
- TIGIT
- AstraZeneca
- Moderna
- lly
- genentech
- AACR
- 키트루다
- 면역항암제
- Eli Lilly
- Kura
- 당뇨치료제
- 자가세포치료제
- roche
- Amgen
- ipsc
- t세포
- 자가면역질환
- sana
- NK세포
- NASDAQ
- ALT
- Dawn
- ADC
- Fate